Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous BCMA-CART for Relapsed or Refractory Multiple Myeloma
NCT03492268Phase 1Withdrawn
- Sponsor
- BRL Medicine Inc.
- Start
- Nov 2021
- Primary completion
- Dec 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BCMA-CART in multiple myeloma (MM), sponsored by BRL Medicine Inc. Primary endpoint: Objective Response Rate at 90 days. Planned start Nov 2021; status: withdrawn.
02
Drugs
BCMA-CART
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03492268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03492268.